JP2004531560A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004531560A5 JP2004531560A5 JP2002591001A JP2002591001A JP2004531560A5 JP 2004531560 A5 JP2004531560 A5 JP 2004531560A5 JP 2002591001 A JP2002591001 A JP 2002591001A JP 2002591001 A JP2002591001 A JP 2002591001A JP 2004531560 A5 JP2004531560 A5 JP 2004531560A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- pentahydroxy
- epoxy
- effective amount
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 7
- 206010013774 Dry eye Diseases 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 4
- 238000009736 wetting Methods 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 239000004593 Epoxy Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000699 topical Effects 0.000 claims 1
Claims (10)
- ドライアイおよび眼の湿潤を必要とする他の障害の処置のための薬学的組成物であって、薬学的受容可能なキャリアおよび薬学的有効量の22,29−エポキシ−3,4,6,7,29−ペンタヒドロキシ−(3α,4β,5α,6α,7β,14β,22S)−スチグマスタン−15−オンを含む、組成物。
- 請求項1に記載の薬学的組成物であって、前記22,29−エポキシ−3,4,6,7,29−ペンタヒドロキシ−(3α,4β,5α,6α,7β,14β,22S)−スチグマスタン−15−オンの薬学的有効量が、0.001〜5.0%(w/v)である、組成物。
- 請求項2に記載の薬学的組成物であって、前記22,29−エポキシ−3,4,6,7,29−ペンタヒドロキシ−(3α,4β,5α,6α,7β,14β,22S)−スチグマスタン−15−オンの薬学的有効量が、0.001〜1.0%(w/v)である、組成物。
- 請求項1に記載の薬学的組成物であって、前記組成物が、前記眼への局所投与のために処方される、組成物。
- 請求項1に記載の薬学的組成物であって、前記ドライアイおよび眼の湿潤を必要とする他の障害が、屈折手術に関連するドライアイの症状である、組成物。
- ドライアイおよび眼の湿潤を必要とする他の障害の処置用の医薬の製造のための使用であって、薬学的組成物が、薬学的受容可能なキャリアおよび薬学的有効量の22,29−エポキシ−3,4,6,7,29−ペンタヒドロキシ−(3α,4β,5α,6α,7β,14β,22S)−スチグマスタン−15−オンを含む、使用。
- 請求項6に記載の使用であって、前記22,29−エポキシ−3,4,6,7,29−ペンタヒドロキシ−(3α,4β,5α,6α,7β,14β,22S)−スチグマスタン−15−オンの薬学的有効量が、0.001〜5.0%(w/v)である、使用。
- 請求項6に記載の使用であって、前記22,29−エポキシ−3,4,6,7,29−ペンタヒドロキシ−(3α,4β,5α,6α,7β,14β,22S)−スチグマスタン−15−オンの薬学的有効量が、0.001〜1.0%(w/v)である、使用。
- 請求項6に記載の使用であって、前記組成物が、前記眼への局所投与のために処方される、使用。
- 請求項6に記載の使用であって、前記ドライアイおよび眼の湿潤を必要とする他の障害が、屈折手術に関連するドライアイの症状である、使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29250001P | 2001-05-21 | 2001-05-21 | |
PCT/US2002/015784 WO2002094284A1 (en) | 2001-05-21 | 2002-05-17 | Method of treating dry eye disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004531560A JP2004531560A (ja) | 2004-10-14 |
JP2004531560A5 true JP2004531560A5 (ja) | 2006-01-05 |
Family
ID=23124938
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002591001A Pending JP2004531560A (ja) | 2001-05-21 | 2002-05-17 | ドライアイ障害を処置する方法 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20030008853A1 (ja) |
EP (1) | EP1392322A1 (ja) |
JP (1) | JP2004531560A (ja) |
CN (1) | CN1239161C (ja) |
BR (1) | BR0209882A (ja) |
CA (1) | CA2447918A1 (ja) |
MX (1) | MXPA03010633A (ja) |
PL (1) | PL367097A1 (ja) |
WO (1) | WO2002094284A1 (ja) |
ZA (1) | ZA200308770B (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602005016392D1 (de) | 2004-03-25 | 2009-10-15 | Bausch & Lomb | Verwendung von loteprednoletabonat zur behanldung von trockenen augen |
AU2007253776B2 (en) * | 2006-05-19 | 2012-04-26 | Arrowhead Research Corporation | RNAi-mediated inhibition of tumor necrosis factor alpha-related conditions |
US7691811B2 (en) * | 2006-05-25 | 2010-04-06 | Bodor Nicholas S | Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US527851A (en) * | 1894-10-23 | Process of reducing aluminium | ||
US3991759A (en) * | 1975-10-28 | 1976-11-16 | Alza Corporation | Method and therapeutic system for treating aqueous deficient dry eye |
US4131651A (en) * | 1977-10-25 | 1978-12-26 | Barnes-Hind Pharmaceuticals, Inc. | Treatment of dry eye |
US4409205A (en) * | 1979-03-05 | 1983-10-11 | Cooper Laboratories, Inc. | Ophthalmic solution |
US4370325A (en) * | 1979-03-30 | 1983-01-25 | Dermik Laboratories | Pharmaceutical compositions and method of treatment |
US4883658A (en) * | 1986-04-28 | 1989-11-28 | Holly Frank J | Ophthalmic solution for treatment of dry-eye syndrome |
US4744980A (en) * | 1986-04-28 | 1988-05-17 | Holly Frank J | Ophthalmic solution for treatment of dry eye syndrome |
US4804539A (en) * | 1986-07-28 | 1989-02-14 | Liposome Technology, Inc. | Ophthalmic liposomes |
US4818537A (en) * | 1986-10-21 | 1989-04-04 | Liposome Technology, Inc. | Liposome composition for treating dry eye |
US4966773A (en) * | 1986-11-25 | 1990-10-30 | Alcon Laboratories, Inc. | Topical ophthalmic compositions containing microfine retinoid particles |
US4914088A (en) * | 1987-04-02 | 1990-04-03 | Thomas Glonek | Dry eye treatment solution and method |
US5075104A (en) * | 1989-03-31 | 1991-12-24 | Alcon Laboratories, Inc. | Ophthalmic carboxy vinyl polymer gel for dry eye syndrome |
US5174988A (en) * | 1989-07-27 | 1992-12-29 | Scientific Development & Research, Inc. | Phospholipid delivery system |
US5583150A (en) * | 1989-08-18 | 1996-12-10 | Alcon Laboratories, Inc. | 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases |
US5041434A (en) * | 1991-08-17 | 1991-08-20 | Virginia Lubkin | Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application |
ZA912797B (en) * | 1990-05-29 | 1992-12-30 | Boston Ocular Res | Dry eye treatment process and solution |
ES2084722T3 (es) * | 1990-05-29 | 1996-05-16 | Boston Ocular Res | Composicion para tratamiento del ojo seco. |
DK0495421T3 (da) * | 1991-01-15 | 1996-12-09 | Alcon Lab Inc | Anvendelse af carragenaner i topiske ophthalmiske sammensætninger |
US5958912A (en) * | 1992-04-21 | 1999-09-28 | The Schepens Eye Research Institute, Inc. | Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β |
US6107289A (en) * | 1992-04-21 | 2000-08-22 | The Schepens Eye Research Institute, Inc. | Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β |
JPH07508716A (ja) * | 1992-04-21 | 1995-09-28 | ザ スキーペンズ アイ リサーチ インスティテュート,インコーポレイテッド | シェーグレン症候群における眼のアンドロゲン療法 |
US5506221A (en) * | 1992-12-24 | 1996-04-09 | University Of British Columbia | Contignasterol, and related 3-alpha hydroxy-6-alpha hydroxy-7-beta hydroxy-15-keto-14-beta steroids useful as anti-inflammatory and anti-thrombosis agents |
US5696166A (en) * | 1995-10-31 | 1997-12-09 | Yanni; John M. | Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders |
WO1997020578A1 (en) * | 1995-12-04 | 1997-06-12 | University Of Miami | Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance |
US6046185A (en) * | 1996-07-11 | 2000-04-04 | Inflazyme Pharmaceuticals Ltd. | 6,7-oxygenated steroids and uses related thereto |
US6071904A (en) * | 1996-12-11 | 2000-06-06 | Alcon Laboratories, Inc. | Process for manufacturing ophthalmic suspensions |
US5800807A (en) * | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
WO1998053806A1 (fr) * | 1997-05-26 | 1998-12-03 | New Vision Co., Ltd. | Compositions medicinales a administration topique renfermant les vitamines d et les vitamines k |
US6096733A (en) * | 1998-12-10 | 2000-08-01 | Virginia Lubkin | Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application |
WO2002086076A2 (en) * | 2001-04-19 | 2002-10-31 | Bristol-Myers Squibb Company | Polynucleotides and polypeptides associated with the nf-kb pathway |
US20040076691A1 (en) * | 2002-01-16 | 2004-04-22 | David Haines | Anti-inflammatory formulations |
-
2002
- 2002-05-17 PL PL02367097A patent/PL367097A1/xx unknown
- 2002-05-17 CN CNB028102428A patent/CN1239161C/zh not_active Expired - Fee Related
- 2002-05-17 EP EP02746411A patent/EP1392322A1/en not_active Withdrawn
- 2002-05-17 JP JP2002591001A patent/JP2004531560A/ja active Pending
- 2002-05-17 BR BR0209882-2A patent/BR0209882A/pt not_active IP Right Cessation
- 2002-05-17 US US10/150,199 patent/US20030008853A1/en not_active Abandoned
- 2002-05-17 WO PCT/US2002/015784 patent/WO2002094284A1/en not_active Application Discontinuation
- 2002-05-17 CA CA002447918A patent/CA2447918A1/en not_active Abandoned
-
2003
- 2003-11-11 ZA ZA200308770A patent/ZA200308770B/en unknown
- 2003-11-19 MX MXPA03010633A patent/MXPA03010633A/es not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9919050B2 (en) | Compositions comprising azelastine | |
JPS6034925B2 (ja) | 持続性鼻腔用製剤およびその製造法 | |
WO2006017505A3 (en) | Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases | |
TW201016209A (en) | Intranasal compositions, dosage forms and methods of treatments | |
AU2002361918A1 (en) | Aerosolized decongestants for the treatment of sinusitis | |
EP1420760A2 (en) | Aerosolized decongestants for the treatment of sinusitis | |
JP2006503913A5 (ja) | ||
JP2009501797A5 (ja) | ||
AU2003301747A8 (en) | Pharmaceutical compositions suitable for the treatment of ophthalmic diseases | |
ES2266288T3 (es) | Pulverizador nasal tixotropico. | |
JP2005508963A5 (ja) | ||
JP2004531560A5 (ja) | ||
JP2002540148A5 (ja) | ||
JP2007504268A5 (ja) | ||
NO20020342D0 (no) | Formuleringer av steroidlösninger for inhalasjonsadministrasjon | |
KR100910848B1 (ko) | 알러지성 비염 치료약물을 유효성분으로 함유하는 비강분무용 마이크로스피어 및 이의 제조방법 | |
JPH0977656A (ja) | 点眼用エアゾル組成物 | |
AU2012201428B2 (en) | Compositions comprising azelastine and methods of use thereof | |
JP2002523362A5 (ja) | ||
WO2007046113A3 (en) | Novel pharmaceutical composition comprising alkaloid and process thereof | |
CN101138586A (zh) | 核黄青黛口腔溃疡贴片 | |
JP2006503049A5 (ja) | ||
Lambert | A review of the active ingredients and excipients in cough medicine: ear, nose and throat | |
Lorber et al. | Desloratadine is effective at relieving nasal congestion, as demonstrated in three placebo-controlled trials in patients with seasonal allergic rhinitis | |
Chaplin et al. | Nasal steroids: concise guide to properties and recommended use |